S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
Log in

Generex Biotechnology Stock Forecast, Price & News

0.00 (0.00 %)
(As of 02/25/2021 12:00 AM ET)
Today's Range
Now: $0.44
50-Day Range
MA: $0.40
52-Week Range
Now: $0.44
Volume847,187 shs
Average Volume1.14 million shs
Market Capitalization$47.84 million
P/E RatioN/A
Dividend YieldN/A
Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida.


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:GNBT
Year FoundedN/A



Sales & Book Value

Annual Sales$2.66 million
Book Value($0.10) per share


Net Income$-33,330,000.00
Net Margins-1,722.93%


Market Cap$47.84 million
Next Earnings Date3/19/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

0.75 out of 5 stars

Medical Sector

1180th out of 1,957 stocks

Pharmaceutical Preparations Industry

538th out of 771 stocks

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
0.00 (0.00 %)
(As of 02/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GNBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GNBT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Generex Biotechnology (OTCMKTS:GNBT) Frequently Asked Questions

What stocks does MarketBeat like better than Generex Biotechnology?

Wall Street analysts have given Generex Biotechnology a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Generex Biotechnology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Generex Biotechnology's next earnings date?

Generex Biotechnology is scheduled to release its next quarterly earnings announcement on Friday, March 19th 2021.
View our earnings forecast for Generex Biotechnology

How were Generex Biotechnology's earnings last quarter?

Generex Biotechnology Co. (OTCMKTS:GNBT) released its quarterly earnings results on Monday, December, 21st. The company reported ($0.15) earnings per share for the quarter. The business earned $0.09 million during the quarter. Generex Biotechnology had a negative trailing twelve-month return on equity of 1,712.86% and a negative net margin of 1,722.93%.
View Generex Biotechnology's earnings history

How has Generex Biotechnology's stock been impacted by COVID-19?

Generex Biotechnology's stock was trading at $0.7170 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GNBT stock has decreased by 39.3% and is now trading at $0.4350.
View which stocks have been most impacted by COVID-19

Who are Generex Biotechnology's key executives?

Generex Biotechnology's management team includes the following people:
  • Mr. Joseph Moscato, CEO, Pres & Chairman (Age 57, Pay $103.14k)
  • Mr. Mark Corrao, CFO & Treasurer (Age 63, Pay $27.54k)
  • Mr. Terry R. Thompson, Chief Operating Officer (Age 63, Pay $42.5k)
  • Mr. Andrew Ro, Chief Investment Officer, Sr. VP of Investments & Director (Age 50, Pay $22k)
  • Mr. Anthony S. Crisci CPA, Esq., Chief Legal Officer (Age 51, Pay $30k)
  • Mr. Anthony J. Dolisi, Chief Commercial Officer (Age 56)
  • Dr. Jason Bradley Terrell, Chief Scientific Officer & Chief Medical Officer (Age 41)
  • Ms. Michelle Starr, Chief Marketing Officer
  • Mr. Richard D. Purcell, Exec. VP of Research & Drug Devel. (Age 60)

Who are some of Generex Biotechnology's key competitors?

What other stocks do shareholders of Generex Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Generex Biotechnology investors own include SELLAS Life Sciences Group (SLS), (UNISQ) (UNISQ), Amgen (AMGN), Novavax (NVAX), VBI Vaccines (VBIV), iBio (IBIO), Inovio Pharmaceuticals (INO), Vaxart (VXRT), Gilead Sciences (GILD) and Quest Diagnostics (DGX).

What is Generex Biotechnology's stock symbol?

Generex Biotechnology trades on the OTCMKTS under the ticker symbol "GNBT."

How do I buy shares of Generex Biotechnology?

Shares of GNBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Generex Biotechnology's stock price today?

One share of GNBT stock can currently be purchased for approximately $0.44.

How much money does Generex Biotechnology make?

Generex Biotechnology has a market capitalization of $47.84 million and generates $2.66 million in revenue each year.

How many employees does Generex Biotechnology have?

Generex Biotechnology employs 15 workers across the globe.

What is Generex Biotechnology's official website?

The official website for Generex Biotechnology is www.generex.com.

Where are Generex Biotechnology's headquarters?

Generex Biotechnology is headquartered at 10102 USA TODAY WAY, MIRAMAR FL, 33025.

How can I contact Generex Biotechnology?

Generex Biotechnology's mailing address is 10102 USA TODAY WAY, MIRAMAR FL, 33025. The company can be reached via phone at 416-364-2551 or via email at [email protected]

This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.